AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01142986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low intensity care
Description: During the first 3-months (13 weeks), subjects will be scheduled to attend one individual counseling session per month. Subjects will not be required to attend any group counseling sessions during this time. After the first 3-months of care, subjects will start usual counseling care, at which time they will be required to attend one individual counseling session per week, and may be required to attend additional individual and group counseling sessions each week for missed sessions or continued use of drugs or alcohol.
Study NCT01142986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voucher reinforcement
Description: Subjects will receive usual counseling care during the 26 weeks of study participation.They will be required to attend one individual counseling session per week, and will be required to attend additional individual and group sessions each week for missed session or continued use of drugs or alcohol.In addition, subjects in this condition will have the opportunity to earn voucher incentives each week during the first 13 weeks of care.These incentives can be earned by taking daily methadone doses and attending all scheduled counseling sessions (individual and group).The first voucher is worth $12.00, and each voucher after that is worth an additional $13.50. Bonuses of $30.00 will be awarded for each 3 consecutive weeks of compliance.The total amount possible to earn in the study is $1329.00. Each week that the subject is not compliant,they will not earn a voucher and the value of the next voucher will be reset to $12.00.The vouchers can be used for goods and services in the community.
Study NCT00903461 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EGFR Antisense DNA
Description: * Intratumoral EGFR AS injections weekly x 7 weeks (or less if there is no identifiable tumor), starting 2 weeks prior to radiation. The first EGFR AS injection must be given after cetuximab is administered. Subsequent EGFR AS injections can be given before or after cetuximab is administered. Injections will be in the primary and/or lymph nodes. One site will be injected per weekly session. If it is necessary the antisense injection can be scheduled within 1 business day of the original schedule date and then resume the original schedule~* EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. The same lesion (primary tumor or lymph node) will be injected during treatment.
Study NCT02126371 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: LEO32731
Study NCT01270854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasmalyte A
Description: Intravenous fluid
Study NCT01270854 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Intravenous fluid
Study NCT04268589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality game
Description: routine
Study NCT01439568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2510924
Description: Administered subcutaneous injection
Study NCT01439568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered intravenously
Study NCT01439568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously
Study NCT01439568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Administered intravenously
Study NCT01439568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Administered intravenously
Study NCT03500471 — intervention group
Intervention type: PROCEDURE
Intervention: Robotic-assisted Total Gastrectomy
Description: Robotic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose robotic-assisted total gastrectomy and exclusing T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
Study NCT03500471 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic-assisted Total Gastrectomy
Description: Laparoscopic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose laparoscopic-assisted total gastrectomy and exclusing T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
Study NCT01323946 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational vaccine GSK1562902A
Description: Three intramuscular injections
Study NCT03300310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nursing visit
Description: nursing visit at patient home
Study NCT03300310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no nursing visit
Description: the patient take his treatment without nursing visit
Study NCT00003254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethynyluracil
Description: 10mg/m2/dose, PO, Days 1-28, q 5wk
Study NCT00003254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 1.0mg/m2/dose, PO, Days 1-28 BID, q 5wk
Study NCT03525093 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypnosis
Description: 5 session of group hypnosis, each 90 minutes, to reduce subjective levels of stress, improve coping with stress. Additional audiotapes of hypnosis sessions as homework.~Participants receive a health education booklet on improving coping with stress.
Study NCT03525093 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health education
Description: Participants receive a health education booklet on improving coping with stress.
Study NCT03272516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based cognitive therapy (MBCT)
Description: Mindfulness Based Cognitive Therapy (MBCT). This group receives 8 weeks of MBCT in addition to usual treatment (TAU). The MBCT consists of weekly group sessions of 2,5 hours, where participants receive cognitive therapy as well as mindfulness meditation. This group is also assigned homework, according to the MBCT protocol.
Study NCT03272516 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: Usual treatment prescribed by each physician, specifically interview therapy, cognitive therapy, antidepressants and/or anxiolytics as well as a mixture of all of the above.
Study NCT03272516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Description: Usual treatment prescribed by each physician, specifically interview therapy, cognitive therapy, antidepressants and/or anxiolytics as well as a mixture of all of the above.
Study NCT04647071 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Garlic and onion concentrate
Description: Garlic extract concentrate (equivalent to 2 garlic cloves) and onion extract concentrate (equivalent to 1 onion).
Study NCT04647071 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Garlic and onion concentrate
Description: Garlic extract concentrate (equivalent to 2 garlic cloves) and onion extract concentrate (equivalent to 1 onion).
Study NCT04647071 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Microcrystalline cellulose
Study NCT04647071 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: Microcrystalline cellulose
Study NCT00600444 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Venae sectio
Description: surgical preparation of the cephalic vene to insert a totally implantable access port.
Study NCT00600444 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Punction of V. subclavia
Description: radiological punction of the v. subclavia with Seldinger technique to implant a totally implantable access port
Study NCT04601922 — intervention group
Intervention type: OTHER
Intervention: Semi-structured interview
Description: The interview will have the audio recorded, and will explore the ideas of each participant around long term cardiovascular care pathways
Study NCT02193451 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urodynamics
Description: Diagnostic test for urinary storage and voiding function
Study NCT02193451 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Usual care
Study NCT02193451 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Study NCT03711266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PE-PC
Description: PE-PC treatment will follow the PE-PC manual and patient workbook. Treatment content for PE-PC is drawn from the PE model and condensed so as to deliver the most efficacious components of PE. PE-PC consists of four, 30-minute appointments scheduled approximately once a week over 4-6 weeks
Study NCT03518723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-linear Periodized Resistance Training
Description: 8 week non-linear periodized resistance training intervention, 3 sessions per week, 60 minutes per session
Study NCT03518723 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training
Description: 8 week resistance training intervention, 3 sessions per week, 60 minutes per session
Study NCT01475786 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose: 16 mg Engensis (VM202)
Description: Subjects in the Low Dose Group (8mg VM202 / leg) will receive the following intramuscular injections in each calf:~Day 0 - 32 injections / calf:~• 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)~Day 14 - 32 injections / calf:~• 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)
Study NCT01475786 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: High Dose: 32 mg Engensis (VM202)
Description: Subjects in the High Dose Group (16 mg VM202 / leg) will receive the following intramuscular injections in each calf:~Day 0~• 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf)~Day 14~• 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf)
Study NCT04210102 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Chest radiography (CR)
Description: The chest X-ray is a medical imaging examination that provides images of the lungs through the X-ray pulse.
Study NCT01917370 — intervention group
Intervention type: PROCEDURE
Intervention: surgical treatment
Description: all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
Study NCT01641055 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salmon protein hydrolysate
Description: 2.5g salmon protein hydrolysate per day for 8wk.
Study NCT01641055 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Herring protein hydrolysate
Description: 2.5g herring protein hydrolysate per day for 8wk.
Study NCT01641055 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Cod protein
Description: 2.5g cod protein per day for 8wk.
Study NCT01641055 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Milk protein
Description: 2.5g milk protein per day for 8wk.
Study NCT03366779 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 6mm annular closure device
Description: 6MM Barricaid annular closure device implantation following standard lumbar discectomy
Study NCT00853073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: 1.0mg (0.04 cc of 25 mg/ml subconjunctival bevacizumab following bleb needling procedure
Study NCT00853073 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: balanced salt solution
Description: 0.04 cc of balanced salt solution injected to the bleb following bleb needling procedure
Study NCT00935051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Picture + MMPs and TIMP1 at week 0 and week 4
Description: Sample of wound fluid will be collected using a non traumatic procedure at week 0 and week 4. This will allow to assess the level of MMP9, MMP13, MMP1 and TIMP1. A numeric photograph of the wound will be taken at week 0, week 4 and week 12 in order to assess wound area.
Study NCT03519386 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: G2-TR intraocular implant containing travoprost
Description: Provided in Arm/Group descriptions.
Study NCT01396876 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: clown
Description: a distraction technique is performed by a clown during venipuncture
Study NCT01188993 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: early septic shock
Description: Each patient will be assessed by both the transpulmonary thermodilution and Transesophageal Echocardiography.
Study NCT00783692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vedolizumab
Description: Vedolizumab for intravenous infusion
Study NCT00783692 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous infusion
Study NCT01657318 — intervention group
Intervention type: OTHER
Intervention: Olivamine containing wound care products
Description: Continuous wound care with Olivamine containing products until wound closure. Intake of dietary supplement of 1 capsule for 60 days.
Study NCT03519386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham surgery + active-comparator eye drops
Description: Sham surgery plus postoperative active-comparator eye drops (timolol maleate ophthalmic solution, 0.5%).
Study NCT01316354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread types
Description: Bread with 50 g available carbohydrate
Study NCT02929069 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ESTEEM
Description: ESTEEM is a 10-session intervention based on the Unified Protocol, an individually-delivered CBT intervention with efficacy for reducing stress-sensitive mental health disorders (e.g., depression, anxiety) by enhancing emotion regulation skills; reducing avoidance patterns; and improving motivation and self-efficacy for behavior change.
Study NCT02929069 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CMHT
Description: CMHT is the current standard of care for LGB individuals who seek mental, behavioral, or sexual health care is LGB-affirmative therapy.The practice of LGB-affirmative therapy is outlined across 21 guidelines published by the American Psychological Association.
Study NCT02929069 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VCT
Description: Voluntary Counselling and Testing (VCT).
Study NCT02929069 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VCT
Description: Voluntary Counselling and Testing (VCT).
Study NCT00362752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Description: 400 mg po bid
Study NCT00362752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 400 mg po bid
Study NCT01289743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept 25 mg subcutaneously twice a week
Study NCT00765089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Isolation of pulmonary veins with Bipolar radiofrequency ablation
Study NCT01498874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
Study NCT01498874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gevokizumab
Description: Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
Study NCT01368120 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IV Clear™ Dressing
Description: Polyurethane film, silicone adhesive dressing with chlorhexidine and silver
Study NCT03767101 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy
Description: In all three treatment arms, licensed therapists/trainee therapists perform a cognitive behavior therapy (CBT) under conditions of the German health care system. All treatments are based on individualized treatment plans for each patient. Therapists are supervized by an CBT expert therapist in the outpatient treatment center. On average every forth session is supervized. The total duration of treatment is variable, oriented on patients symptoms and treatment goals.
Study NCT03767101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: In all three treatment arms, licensed therapists/trainee therapists perform a cognitive behavior therapy (CBT) under conditions of the German health care system. All treatments are based on individualized treatment plans for each patient. Therapists are supervized by an CBT expert therapist in the outpatient treatment center. On average every forth session is supervized. The total duration of treatment is variable, oriented on patients symptoms and treatment goals.
Study NCT03767101 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive behavioral therapy
Description: In all three treatment arms, licensed therapists/trainee therapists perform a cognitive behavior therapy (CBT) under conditions of the German health care system. All treatments are based on individualized treatment plans for each patient. Therapists are supervized by an CBT expert therapist in the outpatient treatment center. On average every forth session is supervized. The total duration of treatment is variable, oriented on patients symptoms and treatment goals.
Study NCT03647332 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cooled RFA treatment
Description: cooled radiofrequency ablation
Study NCT03647332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid Drug
Description: steroid injection
Study NCT03408340 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paravertebral Nerve Block
Description: Participants will be induced for anesthesia with propofol 3 milligram/kilogram (mg/kg) or ketamine 2mg/kg (if there is intravenous (IV) access) or sevoflurane with 1 microgram/kilogram (mcg/kg) of fentanyl and 1.2 mg/kg rocuronium once IV access is established. A NIRS pad will be used for cerebral oximetry as well as another NIRS pad for spinal cord oximetry. The patient will be intubated, and then will be positioned laterally for the nerve block at approximately the left T3-4 level. A linear ultrasound probe with a sterile sheath will be used to provide imaging for the paravertebral nerve block. The injected solution will be 1 milliliter/kilogram (mL/kg) of 0.2% ropivacaine with 5 mcg/mL (1:200,000) epinephrine. Fentanyl may be used as needed for additional analgesia and anesthesia will be maintained with sevoflurane. The skin will not be infiltrated with additional local anesthetic at the conclusion of the case.
Study NCT03408340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Anesthesia
Description: Participants in this arm will be induced for anesthesia with propofol 3mg/kg or ketamine 2mg/kg (if there is intravenous access) or sevoflurane with 1 mcg/kg of fentanyl and 1.2 mg/kg rocuronium once IV access is established. The patient will be intubated; intravenous and intra-arterial access will be obtained and the patient will be positioned for surgery. Fentanyl may be used as needed for additional analgesia and anesthesia will be maintained with sevoflurane. The skin will be infiltrated at the conclusion of surgery with less than 1 mL/kg of 0.25% bupivacaine with epinephrine 1:200,000.
Study NCT04054882 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sabin-IPV and DTaP
Description: simultaneously administration of Sabin-IPV and DTaP
Study NCT04054882 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sabin-IPV
Description: administration of Sabin-IPV only
Study NCT04054882 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP
Description: administration of DTaP only
Study NCT02702999 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clinically-indicated ultrasound
Description: Routine third trimester care with clinically-indicated ultrasound (control)
Study NCT02702999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Serial third trimester ultrasound
Description: Ultrasound evaluation for fetal growth and amniotic fluid will be performed every 4 weeks starting at 30 weeks (intervention group). Thus, if they continue to term, there will be 3 additional ultrasounds exams (30, 34 and 38 weeks).
Study NCT01475786 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control- Placebo (normal saline)
Description: subjects will receive thirty-two (32) 0.5 mL injections of normal saline on Day 0 and Day 14.
Study NCT01475786 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control- Placebo (normal saline)
Description: subjects will receive thirty-two (32) 0.5 mL injections of normal saline on Day 0 and Day 14.